Travel grant 2025 Singapore, Delegation to Singapore, 8 Sep

Purpose and goal

Prolevi Bio is a Clinical stage start up focusing on Drug delivery with its platform tech (with potential to expand to multiple molecules). As a first use case, we have developed a controlled release formulation of T3 (ProT3) for hypothyroid patients (a metabolic disorder with 750M patients worldwide, 80-90% women, underactive thyroid, first in class). With our first successful pilot human Clinical trial with T3 proxy, we have validated our tech, CMC and predictions.

Expected effects and result

1. Secure financing for fundraise 2. Meet branded generics pharma from Singapore 3. Negotiate asia licensing rights

Planned approach and implementation

Attend Asia Bio Partnering conference, network at the conference events and build further relationships.